FibroGen, Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi sold 2,000 shares of the stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $33.45, for a total transaction of $66,900.00. Following the completion of the sale, the director now owns 32,000 shares in the company, valued at $1,070,400. The transaction was disclosed in a filing with the SEC, which is available through this link.
Kalevi Kurkijarvi also recently made the following trade(s):
- On Thursday, June 15th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The stock was sold at an average price of $28.50, for a total transaction of $57,000.00.
- On Tuesday, May 16th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The stock was sold at an average price of $27.40, for a total transaction of $54,800.00.
FibroGen, Inc (FGEN) traded down 0.85% during mid-day trading on Friday, hitting $34.95. 117,313 shares of the stock traded hands. The company’s 50 day moving average is $31.44 and its 200 day moving average is $26.84. The company’s market cap is $2.44 billion. FibroGen, Inc has a 12 month low of $15.60 and a 12 month high of $35.65.
FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.11. The business had revenue of $26.89 million for the quarter, compared to analyst estimates of $26.02 million. FibroGen had a negative return on equity of 36.41% and a negative net margin of 37.60%. On average, analysts expect that FibroGen, Inc will post ($1.85) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: FibroGen, Inc (NASDAQ:FGEN) Director Sells $66,900.00 in Stock” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://stocknewstimes.com/2017/07/21/insider-selling-fibrogen-inc-nasdaqfgen-director-sells-66900-00-in-stock.html.
Several analysts have issued reports on the stock. Goldman Sachs Group, Inc. (The) cut shares of FibroGen from a “buy” rating to a “neutral” rating in a research note on Friday. Jefferies Group LLC began coverage on shares of FibroGen in a research note on Monday, July 10th. They issued a “buy” rating and a $50.00 target price on the stock. Citigroup Inc. restated a “buy” rating and set a $48.00 price objective on shares of FibroGen in a research report on Monday, June 26th. Stifel Nicolaus restated a “buy” rating and set a $38.00 price objective (up previously from $32.00) on shares of FibroGen in a research report on Thursday, June 22nd. Finally, William Blair restated an “outperform” rating on shares of FibroGen in a research report on Monday, June 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $42.17.
Hedge funds have recently bought and sold shares of the stock. Handelsinvest Investeringsforvaltning raised its stake in FibroGen by 102.8% in the second quarter. Handelsinvest Investeringsforvaltning now owns 71,400 shares of the biopharmaceutical company’s stock worth $2,306,000 after buying an additional 36,200 shares during the last quarter. Janus Capital Management LLC raised its stake in FibroGen by 1.1% in the first quarter. Janus Capital Management LLC now owns 1,363,657 shares of the biopharmaceutical company’s stock worth $33,613,000 after buying an additional 14,882 shares during the last quarter. Credit Suisse AG raised its stake in FibroGen by 173.7% in the first quarter. Credit Suisse AG now owns 134,211 shares of the biopharmaceutical company’s stock worth $3,309,000 after buying an additional 85,169 shares during the last quarter. State Street Corp raised its stake in FibroGen by 11.1% in the first quarter. State Street Corp now owns 1,514,465 shares of the biopharmaceutical company’s stock worth $37,336,000 after buying an additional 150,807 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in FibroGen by 2.4% in the first quarter. Bank of America Corp DE now owns 103,522 shares of the biopharmaceutical company’s stock worth $2,552,000 after buying an additional 2,469 shares during the last quarter. 43.83% of the stock is currently owned by institutional investors and hedge funds.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.
